Research ExplorerPublicationsAspergillus galactomannan antigen for diagnosis and treatmen...

Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis

Standard

Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis. / Soeffker, Gerold; Wichmann, Dominic; Loderstädt, Ulrike; Sobottka, Ingo; Deuse, Tobias; Kluge, Stefan.

In: PROG TRANSPLANT, Vol. 23, No. 1, 01.03.2013, p. 71-4.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Soeffker, G, Wichmann, D, Loderstädt, U, Sobottka, I, Deuse, T & Kluge, S 2013, 'Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis', PROG TRANSPLANT, vol. 23, no. 1, pp. 71-4. https://doi.org/10.7182/pit2013386

APA

Soeffker, G., Wichmann, D., Loderstädt, U., Sobottka, I., Deuse, T., & Kluge, S. (2013). Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis. PROG TRANSPLANT, 23(1), 71-4. https://doi.org/10.7182/pit2013386

Vancouver

Soeffker G, Wichmann D, Loderstädt U, Sobottka I, Deuse T, Kluge S. Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis. PROG TRANSPLANT. 2013 Mar 1;23(1):71-4. https://doi.org/10.7182/pit2013386

Bibtex

@article{8de8a38982314d4a9b3e1e70eeaf5906,
title = "Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis",
abstract = "Invasive aspergillosis, especially neuroaspergillosis, predominantly affects immunocompromised patients such as transplant recipients. Early diagnosis and subsequent early initiation of therapy may improve final outcome. In cerebral aspergillosis, samples for culture or histopathology, the diagnostic reference standard, are often impossible to obtain without risk. Because of these limitations, serological, nucleic acid amplification tests such as polymerase chain reaction or enzyme immunoassay from cerebrospinal fluid appear advantageous for early diagnosis and probably also for therapy monitoring. We report on the successful detection and treatment monitoring by serial testing of galactomannan in cerebrospinal fluid in a patient with neuroaspergillosis after heart transplant.",
keywords = "Antifungal Agents, Antigens, Fungal, Drug Monitoring, Early Diagnosis, Heart Transplantation, Humans, Immunoenzyme Techniques, Male, Membrane Glycoproteins, Meningitis, Fungal, Middle Aged, Neuroaspergillosis, Pyrimidines, Triazoles",
author = "Gerold Soeffker and Dominic Wichmann and Ulrike Loderst{\"a}dt and Ingo Sobottka and Tobias Deuse and Stefan Kluge",
year = "2013",
month = mar,
day = "1",
doi = "10.7182/pit2013386",
language = "English",
volume = "23",
pages = "71--4",
journal = "PROG TRANSPLANT",
issn = "1526-9248",
publisher = "InnoVision Communications",
number = "1",

}

RIS

TY - JOUR

T1 - Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis

AU - Soeffker, Gerold

AU - Wichmann, Dominic

AU - Loderstädt, Ulrike

AU - Sobottka, Ingo

AU - Deuse, Tobias

AU - Kluge, Stefan

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Invasive aspergillosis, especially neuroaspergillosis, predominantly affects immunocompromised patients such as transplant recipients. Early diagnosis and subsequent early initiation of therapy may improve final outcome. In cerebral aspergillosis, samples for culture or histopathology, the diagnostic reference standard, are often impossible to obtain without risk. Because of these limitations, serological, nucleic acid amplification tests such as polymerase chain reaction or enzyme immunoassay from cerebrospinal fluid appear advantageous for early diagnosis and probably also for therapy monitoring. We report on the successful detection and treatment monitoring by serial testing of galactomannan in cerebrospinal fluid in a patient with neuroaspergillosis after heart transplant.

AB - Invasive aspergillosis, especially neuroaspergillosis, predominantly affects immunocompromised patients such as transplant recipients. Early diagnosis and subsequent early initiation of therapy may improve final outcome. In cerebral aspergillosis, samples for culture or histopathology, the diagnostic reference standard, are often impossible to obtain without risk. Because of these limitations, serological, nucleic acid amplification tests such as polymerase chain reaction or enzyme immunoassay from cerebrospinal fluid appear advantageous for early diagnosis and probably also for therapy monitoring. We report on the successful detection and treatment monitoring by serial testing of galactomannan in cerebrospinal fluid in a patient with neuroaspergillosis after heart transplant.

KW - Antifungal Agents

KW - Antigens, Fungal

KW - Drug Monitoring

KW - Early Diagnosis

KW - Heart Transplantation

KW - Humans

KW - Immunoenzyme Techniques

KW - Male

KW - Membrane Glycoproteins

KW - Meningitis, Fungal

KW - Middle Aged

KW - Neuroaspergillosis

KW - Pyrimidines

KW - Triazoles

U2 - 10.7182/pit2013386

DO - 10.7182/pit2013386

M3 - SCORING: Journal article

C2 - 23448824

VL - 23

SP - 71

EP - 74

JO - PROG TRANSPLANT

JF - PROG TRANSPLANT

SN - 1526-9248

IS - 1

ER -